scholarly journals Effects of Menopausal Hormone Therapy on Uterine Myoma in Menopausal Women

2013 ◽  
Vol 19 (3) ◽  
pp. 123 ◽  
Author(s):  
IK Jin Chang ◽  
Gi Youn Hong ◽  
Young Lim Oh ◽  
Byoung Ryun Kim ◽  
Seong Nam Park ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Uterine Myoma ◽  
Menopausal Women

THE PROBLEM OF OSTEOPOROSIS IN MENOPAUSAL WOMEN AND POSSIBLE SOLUTIONS

2021 ◽  
Vol 2 (1) ◽  
pp. 15-17
Author(s):  
Maiorova M.O.
Keyword(s):  
Hormone Therapy ◽  
Bone Tissue ◽  
Calcium Metabolism ◽  
Management Strategy ◽  
Menopausal Hormone Therapy ◽  
Effective Management ◽  
Treatment Of Osteoporosis ◽  
Menopausal Women ◽  
Prevention And Treatment

41 women with osteoporosis were examined. The age of the examined people ranged from 50 to 60 years. All the women were postmenopausal. As a result of the study, it was found that the most effective management strategy for such patients is a combination of menopausal hormone therapy and non-hormonal drugs that affect calcium metabolism in bone tissue, improve its metabolism and reduce resorption. If there are contraindications to MGT, prevention and treatment of osteoporosis should also be carried out using the appointment of non-hormonal drugs. In this case, the use of ipriflavone is effective.

Use of menopausal hormone therapy in the correction of cognitive impairment in menopausal women

2018 ◽  
Vol 12_2018 ◽  
pp. 157-162 ◽  
Author(s):  
Gasparyan S.A. Gasparyan ◽  
Drosova L.D. Drosova ◽  
Karpov S.M. Karpov ◽  
Khripunova A.A. Khripunova ◽  
Keyword(s):  
Cognitive Impairment ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Menopausal Women

scholarly journals Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France

PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
pp. e78016 ◽  
Author(s):  
Emilie Cordina-Duverger ◽  
Thérèse Truong ◽  
Antoinette Anger ◽  
Marie Sanchez ◽  
Patrick Arveux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Case Control Study ◽  
Case Control ◽  
Menopausal Hormone Therapy ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Control Study

scholarly journals Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial

Neurology ◽  
2018 ◽  
Vol 90 (16) ◽  
pp. e1404-e1412 ◽  
Author(s):  
Kejal Kantarci ◽  
Nirubol Tosakulwong ◽  
Timothy G. Lesnick ◽  
Samantha M. Zuk ◽  
Val J. Lowe ◽  
...  
Keyword(s):  
White Matter ◽  
Hormone Therapy ◽  
Brain Structure ◽  
Cognitive Change ◽  
Menopausal Hormone Therapy ◽  
Pittsburgh Compound B ◽  
Ventricular Volumes ◽  
Menopausal Women ◽  
Dorsolateral Prefrontal ◽  
Global Brain

ObjectiveThe effects of 2 frequently used formulations of menopausal hormone therapy (mHT) on brain structure and cognition were investigated 3 years after the end of a randomized, placebo-controlled trial in recently menopausal women with good cardiovascular health.MethodsParticipants (aged 42–56 years; 5–36 months past menopause) were randomized to one of the following: 0.45 mg/d oral conjugated equine estrogen (oCEE); 50 μg/d transdermal 17β-estradiol (tE2); or placebo pills and patch for 4 years. Oral progesterone (200 mg/d) was given to mHT groups for 12 days each month. MRIs were performed at baseline, at the end of 4 years of mHT, and 3 years after the end of mHT (n = 75). A subset of participants also underwent Pittsburgh compound B–PET (n = 68).ResultsVentricular volumes increased more in the oCEE group compared to placebo during the 4 years of mHT, but the increase in ventricular volumes was not different from placebo 3 years after the discontinuation of mHT. Increase in white matter hyperintensity volume was similar in the oCEE and tE2 groups, but it was statistically significantly greater than placebo only in the oCEE group. The longitudinal decline in dorsolateral prefrontal cortex volumes was less in the tE2 group compared to placebo, which correlated with lower cortical Pittsburgh compound B uptake. Rates of global cognitive change in mHT groups were not different from placebo.ConclusionsThe effects of oCEE on global brain structure during mHT subside after oCEE discontinuation but white matter hyperintensities continue to increase. The relative preservation of dorsolateral prefrontal cortical volume in the tE2 group over 7 years indicates that mHT may have long-term effects on the brain.Classification of evidenceThis study provides Class III evidence that the rates of change in global brain volumes and cognitive function in recently menopausal women receiving mHT (tE2 or oCEE) were not significantly different from women receiving placebo, as measured 3 years after exposure to mHT.

scholarly journals Effect of Menopausal Hormone Therapy on the Vaginal Microbiota and Genitourinary Syndrome of Menopause in Chinese Menopausal Women

2020 ◽  
Vol 11 ◽  
Author(s):  
Lulu Geng ◽  
Wenjun Huang ◽  
Susu Jiang ◽  
Yanwei Zheng ◽  
Yibei Zhou ◽  
...  
Keyword(s):  
Microbial Diversity ◽  
Hormone Therapy ◽  
Anaerobic Bacteria ◽  
Vaginal Microbiota ◽  
Menopausal Hormone Therapy ◽  
Rrna Gene ◽  
Genitourinary Syndrome Of Menopause ◽  
Menopausal Women ◽  
Significant Difference ◽  
Genitourinary Syndrome

Genitourinary syndrome of menopause (GSM) is a chronic and progressive condition with a series of vulvovaginal, sexual, and lower urinary tract discomforts, mainly due to hypoestrogenism. Menopausal hormone therapy (MHT) has generally been considered as the most effective treatment for GSM. In addition, vaginal microbiota is of particular significance to gynecological and reproductive illnesses and potentially has some intimate connections with GSM. Consequently, we sought to evaluate how MHT impacts the composition and structure of vaginal microbiota while alleviating GSM in Chinese menopausal women aged 45–65 years, which has not been investigated previously. 16S rRNA gene sequencing was performed to analyze microbial diversity and composition using vaginal swabs obtained from 100 menopausal women, classified as MHT women who have been taking tibolone regularly (n = 50) and non-treated women who never received any treatment (n = 50). Vaginal Health Index Score (VHIS) and GSM symptoms inquiry were also performed. We found that the vaginal microbial diversity decreased and that the abundance of Lactobacillus increased to be the dominant proportion significantly in the MHT group, in considerable contrast to vaginal microbiota of the non-treated group, which significantly comprised several anaerobic bacteria, namely, Gardnerella, Prevotella, Escherichia-Shigella, Streptococcus, Atopobium, Aerococcus, Anaerotruncus, and Anaerococcus. In this study, women without any MHT had significantly more severe GSM symptoms than those receiving tibolone, especially with regard to vulvovaginal dryness and burning, as well as decreased libido (P < 0.01). However, there was no significant difference in the severity of urological symptoms between the groups (P > 0.05). Furthermore, Lactobacillus was demonstrated to be associated with VHIS positively (r = 0.626, P < 0.001) and with GSM negatively (r = −0.347, P < 0.001). We also identified Chlamydia (r = 0.277, P < 0.01) and Streptococcus (r = 0.270, P < 0.01) as having a prominent association with more serious GSM symptoms. Our study provided an elucidation that MHT could notably alleviate GSM and conspicuously reshape the composition of the vaginal microbiota, which is of extreme importance to clinical practice for the management of GSM.

scholarly journals 647Use of menopausal hormone therapy before and after ovarian cancer diagnosis and ovarian cancer survival

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Nina Renhua Na ◽  
Susan J Jordan ◽  
Andreas Obermair ◽  
Penelope M Webb ◽  
Keyword(s):  
Ovarian Cancer ◽  
Propensity Score ◽  
Hormone Therapy ◽  
Cancer Survival ◽  
Menopausal Hormone Therapy ◽  
Cancer Prognosis ◽  
Confounding By Indication ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Ovarian Cancer Survival

Abstract Background Menopausal hormone therapy (MHT) use before ovarian cancer (OvCa) diagnosis has been suggested to improve survival but data on type, duration and use after treatment for OvCa are scarce. Methods We investigated MHT use and OvCa survival among participants with newly diagnosed OvCA in the Ovarian cancer Prognosis And Lifestyle (OPAL) Study. Analysis of pre-diagnosis use was restricted to 661 post-menopausal women and analysis of post-diagnosis use included 254 women aged ≤55-years. We used multivariable Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between MHT and OvCa-specific survival. We used propensity score-based approaches to account for potential bias due to confounding by indication. Results Approximately 14% of post-menopausal women were current/recent users of oestrogen-only (7%) or oestrogen-progestin/unknown MHT (E-P=7%) at the time of diagnosis. In the pre-diagnosis analysis, E-P use was associated with better survival (HR = 0.60, 95%CI=0.37-0.98; HR = 0.93, 95%CI=0.79-1.09 per 5-years/use). The association between oestrogen-only MHT and survival was weaker and non-significant (HR = 0.74, 95%CI=0.47-1.16). Among women ≤55-years at diagnosis, the HR was 0.91 (95%CI=0.50-1.67) for new use after diagnosis regardless of type; and 0.89 (95%CI 0.51-1.54) for any use post-diagnosis compared to never users. Propensity-score-based methods showed similar estimates. Conclusions Pre-diagnosis MHT use is associated with better ovarian cancer survival. Post-diagnosis MHT use might also improve survival for women younger than 55-years, even after accounting for bias due to confounding by indication. Key messages Menopausal hormone therapy may be considered to manage menopausal symptoms in women with ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document